The unique presentation of SARS-CoV-2 Infection in patients with B-cell depletion: definition of 'persistent inflammatory sero-negative COVID'

Article Oncology

Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies

Christina Y. Lee et al.

Summary: Persistent COVID-19 infection is more likely to occur in patients with hematologic malignancies, particularly B-cell lymphomas. Active therapy and diminished T-cell counts are associated with acute mortality, while B cell-depleting therapy is the main cause of rehospitalization. Patients with persistent infection show high viral entropy, especially those with impaired CD8(+) T-cell immunity. These findings highlight the need for additional therapeutic strategies to clear the virus in immunocompromised patients.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Immunology

Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies

Jorge Calderon-Parra et al.

Summary: A retrospective cohort study of 422 patients under anti-CD20 treatment found that patients infected with COVID-19 within 6 months post-treatment had higher rates of hospital admission, mortality, and relapse, as well as longer infectivity of the virus.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Review Oncology

Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)

Simone Cesaro et al.

Summary: SARS-CoV-2 infection can lead to severe outcomes in immunocompromised hematological patients, with high mortality rates observed. Treatment strategies focus on controlling viral replication and inflammation. However, the effectiveness and benefits of preventive and therapeutic measures in hematological patients require further investigation.

LEUKEMIA (2022)

添加到收藏夹

Article Hematology

How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies

Firas El Chaer et al.

Summary: Patients with hematologic malignancies and recipients of HCT are at higher risk of severe COVID-19 and have suboptimal response to vaccines. Treatment options should be selected based on host factors, virus factors, and therapeutic considerations.

BLOOD (2022)

添加到收藏夹

Review Hematology

Vaccination for SARS-CoV-2 in Hematological Patients

Niccolo Riccardi et al.

Summary: This review summarizes the effectiveness and safety of COVID-19 vaccines in patients with hematological malignancies, indicating that these patients generally have weaker humoral responses, but a third mRNA vaccine dose is currently recommended for all patients.

ACTA HAEMATOLOGICA (2022)

添加到收藏夹

Review Hematology

COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response

Ivan Gur et al.

Summary: Patients with hematologic malignancies (HM) are at increased risk of severe and prolonged COVID-19 due to impaired immune function and cytokine release syndrome, highlighting the importance of understanding immunopathology and exploring new treatments for this population.

ACTA HAEMATOLOGICA (2022)

添加到收藏夹

Editorial Material Infectious Diseases

Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity Comment

Dafna Yahav et al.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Takuya Sekine et al.

CELL (2020)

添加到收藏夹

The unique presentation of SARS-CoV-2 Infection in patients with B-cell depletion: definition of 'persistent inflammatory sero-negative COVID'

相关参考文献

导出引文

分享论文